UCI Health | Strategic Alliance Partners

UCI Health is the clinical enterprise of the University of California, Irvine, and the only academic health system in Orange County. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus, UCI Medical Center in Orange, Calif. The 459-bed acute care hospital, listed among America’s Best Hospitals by U.S. News & World Report for 21 consecutive years, provides tertiary and quaternary care, ambulatory and specialty medical clinics, behavioral health and rehabilitation services. UCI Medical Center is home to Orange County’s only National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center and regional burn center. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on Facebook, Instagram, LinkedIn and Twitter.

Connect with us:

Latest from UCI Health

BTK Inhibitors Represent the Preferred Frontline Regimen in CLL

August 13, 2021

Article

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Dr. Ou on the FDA Approval of Pembrolizumab in SCLC

June 18, 2019

Video

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

Dr. Ou on Investigational KRAS Inhibitors in Lung Cancer

June 07, 2019

Video

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

Therapies Moving Though Pipeline for Rare Mutations in NSCLC

May 23, 2019

Article

Sai-Hong I. Ou, MD, PhD, discusses the status of different mutations in lung cancer and the work being done to bring clinically meaningful treatments to the space.

Liquid Biopsies: Complementary Tool in Detecting Driver Mutations in NSCLC

May 22, 2019

Article

Sai-Hong I. Ou, MD, highlights the conveniences of liquid biopsies relative to tissue biopsies, as well as current drawbacks to their use in detecting targetable alterations in lung cancer.

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

March 29, 2019

Article

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

O'Brien Shares Overview of CLL Sequencing

August 10, 2018

Article

Susan M. O'Brien, MD, discusses some of the latest intriguing data in the treatment of chronic lymphocytic leukemia and what this means for physicians and patients.

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

May 05, 2018

Video

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

BTK Inhibitors Mushroom in Blood Cancer Field

January 20, 2017

Article

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11, 2016

Video

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Expert Sheds Light on Role of Next-Generation Agents in CLL

June 01, 2016

Article

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

Idelalisib and Ibrutinib Continue to Advance CLL Treatment

August 26, 2015

Article

Susan M. O'Brien, MD, discusses the impact and the future outlook for idelalisib and ibrutinib in chronic lymphocytic leukemia.

Dr. Ou on Alectinib as Treatment for NSCLC

September 16, 2014

Video

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.